BSX Stock Recent News
BSX LATEST HEADLINES
Boston Scientific Corporation (NYSE:BSX ) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President, Cardiology Conference Call Participants Travis Steed - Bank of America Travis Steed All right. Good morning, everybody.
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Boston Scientific stock is wavering around the buy point of a double-bottom base. The company recently raised its 2025 earnings outlook.
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.
Raising guidance? In this uncertainty?
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.